DDInter1086 DDInter1840
An alkylating agent of value against both hematologic malignancies and solid tumors.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Lomustine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Lomustine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Trabectedin
Lomustine {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Lomustine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is associated with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) is bound by {v} (Compound) Trabectedin
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ifosfamide
Ifosfamide {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Trabectedin
Lomustine {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Thalidomide {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Lomustine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Phenobarbital
Phenobarbital {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Lomustine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)
Lomustine (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Trabectedin (Compound)
Lomustine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Trabectedin (Compound)
Lomustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is associated with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Lomustine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Trabectedin (Compound)
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Trabectedin (Compound)
Lomustine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Trabectedin (Compound)
Lomustine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)